The objective of this study was to unravel the innate immunological response after administration of a novel vaccine (Startvac®, HIPRA, S.A., Amer, Spain), containing the inactivated Escherichia coli J5 strain and the Staphylococcus aureus SP 140 strain expressing Slime Associated Antigenic Complex (SAAC).
Introduction
Mastitis accounts for the largest proportion of antibiotic drug use in the dairy industry (Heringstad et al., 2000) . Ongoing political debates and public concerns about the emergence of antimicrobial resistance and drug residues in milk stress the need for alternatives to antibiotic therapy. In particular, the prophylactic use of antimicrobials is coming under scrutiny. One such use of antibiotics is dry cow therapy. As a consequence, there is an increasing interest in the possibilities to boost the host immune responses.
Both heifers and multiparous cows suffer from immune suppression around parturition, characterized by a higher proportion of less viable blood and milk polymorphonuclear neutrophils (PMN) (Van Oostveldt et al., 2001; . This phenomenon most probably explains the high incidence and increased severity of clinical mastitis in early lactation (Barkema et al., 1998) as PMN play a key role in the elimination of bacteria in the early stages of intramammary infection (IMI) (Paape et al., 2002) .
Enhancement of the immunological response by vaccination is an attractive alternative approach for mastitis prevention and control. Prepartum vaccination did reduce the severity and duration of clinical disease postchallenge in one study (Middleton et al., 2006) , and had a positive effect on milk production in another study (Pellegrino et al., 2008 The aim of this study was to evaluate the effect of administration of the Startvac®vaccine (HIPRA, S.A., Amer, Spain) on milk PMN concentration and viability. Secondly, the production of the antigen-specific antibodies anti-SAAC (against S. aureus) and anti-J5 (against E. coli) in blood was determined over dry period.
Materials and Methods
Eight clinically healthy cows and heifers were selected at the research dairy (Table 1) . Bacteriological culturing was performed at several time points to exclude interference with naturally occurring IMIs. Additionally, quarter milk samples (200 ml) were collected for the quantification of PMN viability at different time points between 15 and 17 DIM (Table 1) .
Bacteriological culture was done as previously described (Piepers et al., 2007) and performed at the lab of the Mastitis and Milk Quality Research Unit (Merelbeke, Belgium). Quarter milk SCC (qSCC) was quantified by electronic counting (Direct Cell Counter, De Laval, Gent, Belgium).
The milk used to isolate PMN was divided into several 50 ml Falcon-tubes and diluted 1:1 with PBS. All tubes were centrifuged (600×g) during 15 minutes, the cream layer and supernatant were removed, and each pellet was suspended into 10 ml PBS. Two pellets were merged together and again centrifuged The concentration of the antigen-specific antibodies anti-SAAC and anti-J5 in blood was determined as previously described (Prenafeta et al., 2010) .
Linear mixed regression models adjusting for clustering of repeated measurements within quarters as well as for clustering of quarters within cows were fit to evaluate the association between the cows' vaccination status before calving and the evolution of qSCC, milk PMN concentration (Log 10 PMN), and milk PMN viability (expressed as the proportion of viable PMN), respectively, in both the inoculated and control quarters. A similar model was fit to evaluate the association between vaccination at 45 and 10 days before calving and the concentration of the antigen-specific antibodies anti-SAAC and anti-J5.
Results and Discussion
All animals remained clinical healthy during the trial period. Challenge did not affect clinical parameters such as heartbeat rate, respiration rate, manure consistence or appetite. The average body temperature 2 hours before inoculation was 38.6°C and 38.8°C for the vaccinated and non-vaccinated animals, respectively, and did not significantly differ between both groups.
In both groups, body temperature slightly increased between 15 and 17 DIM.
The average daily milk yield (MY) per cow was 33.1 liter at the onset of the trial. In the non-vaccinated group average daily MY decreased from 32.3 liter/ day at 15 DIM to 27.3 liter/day at 16 DIM (P = 0.06). In the vaccinated group, no significant differences in average daily MY were observed over time. In both groups of animals, the qSCC of the challenged quarters increased over time. The difference in qSCC between the control and inoculated quarters was substantially higher in the non-vaccinated animals compared with difference in vaccinated animals (P < 0.001). Interestingly, in the vaccinated group the increase of the qSCC in the infected quarters was not significantly different from the qSCC in the control quarters (P = 0.21) (Figure 2 ). Similar results were obtained for the milk PMN concentration (Figure 3 ). The preliminary results on average daily MY and qSCC correspond well with the findings of other studies (Nickerson et al., 1999; Middleton et al., 2006) . The difference in PMN viability between inoculated and control quarters during the trial period did not depend on the vaccination status of the animal. 
